Adda Nathalie
Known title: Sr. VP & Chief Medical OfficerCIK: 0001646976
Associated companies
Transaction History
| ENTA | ▲ Buy | Option Exercise | 16,875 | $1.1M | 4/4/2022 | View on chart |
| ENTA | ▲ Buy | Option Exercise | 9,625 | $419K | 4/4/2022 | View on chart |
| ENTA | ▼ Sell | Open Market | 9,009 | $661K | 4/4/2022 | View on chart |
| ENTA | ▼ Sell | Open Market | 3,200 | $232K | 4/4/2022 | View on chart |
| ENTA | ▼ Sell | Open Market | 18,076 | $1.3M | 4/4/2022 | View on chart |
| ENTA | ▲ Buy | Option Exercise | 6,285 | $305K | 4/4/2022 | View on chart |
| ENTA | ▼ Sell | Open Market | 2,500 | $176K | 4/4/2022 | View on chart |
| ENTA | ▲ Buy | Option Exercise | 2,895 | $140K | 4/1/2022 | View on chart |
| ENTA | ▲ Buy | Option Exercise | 31,664 | $950K | 4/1/2022 | View on chart |
| ENTA | ▼ Sell | Open Market | 42,260 | $3.0M | 4/1/2022 | View on chart |
| ENTA | ▲ Buy | Option Exercise | 16,000 | $503K | 4/1/2022 | View on chart |
| ENTA | ▼ Sell | Open Market | 8,299 | $587K | 4/1/2022 | View on chart |
| ENTA | ▲ Buy | Option Exercise | 12,481 | $542K | 3/2/2022 | View on chart |
| ENTA | ▼ Sell | Open Market | 12,481 | $875K | 3/2/2022 | View on chart |
| ENTA | ▲ Buy | Option Exercise | 24,339 | $1.1M | 3/1/2022 | View on chart |
| ENTA | ▼ Sell | Open Market | 24,239 | $1.7M | 3/1/2022 | View on chart |
| ENTA | ▼ Sell | Open Market | 100 | $7K | 3/1/2022 | View on chart |
| ENTA | ▲ Buy | Grant | 2,419 | $0 | 2/14/2022 | View on chart |
| ENTA | ▼ Sell | Tax Withholding | 954 | $60K | 2/14/2022 | View on chart |
| ENTA | ▲ Buy | Grant | 615 | $0 | 2/14/2022 | View on chart |
| ENTA | ▲ Buy | Option Exercise | 9,200 | $400K | 1/11/2022 | View on chart |
| ENTA | ▲ Buy | Option Exercise | 3,336 | $100K | 1/11/2022 | View on chart |
| ENTA | ▼ Sell | Open Market | 12,536 | $879K | 1/11/2022 | View on chart |
| ENTA | ▼ Sell | Tax Withholding | 842 | $74K | 12/1/2021 | View on chart |
| ENTA | ▲ Buy | Option Exercise | 8,750 | $380K | 12/1/2021 | View on chart |
| ENTA | ▲ Buy | Option Exercise | 4,773 | $232K | 12/1/2021 | View on chart |
| ENTA | ▼ Sell | Open Market | 1,587 | $135K | 12/1/2021 | View on chart |
| ENTA | ▼ Sell | Open Market | 5,736 | $490K | 12/1/2021 | View on chart |
| ENTA | ▼ Sell | Open Market | 2,700 | $233K | 12/1/2021 | View on chart |
| ENTA | ▼ Sell | Open Market | 1,500 | $131K | 12/1/2021 | View on chart |
| ENTA | ▼ Sell | Open Market | 900 | $79K | 12/1/2021 | View on chart |
| ENTA | ▼ Sell | Open Market | 899 | $80K | 12/1/2021 | View on chart |
| ENTA | ▼ Sell | Open Market | 201 | $18K | 12/1/2021 | View on chart |
| ENTA | ▲ Buy | Grant | 6,800 | $0 | 11/19/2021 | View on chart |
| ENTA | ▲ Buy | Option Exercise | 9,547 | $463K | 11/1/2021 | View on chart |
| ENTA | ▼ Sell | Open Market | 1,952 | $165K | 11/1/2021 | View on chart |
| ENTA | ▼ Sell | Open Market | 7,495 | $637K | 11/1/2021 | View on chart |
| ENTA | ▼ Sell | Open Market | 100 | $9K | 11/1/2021 | View on chart |
| ENTA | ▲ Buy | Option Exercise | 4,047 | $176K | 10/11/2021 | View on chart |
| ENTA | ▼ Sell | Open Market | 4,047 | $285K | 10/11/2021 | View on chart |
| ENTA | ▲ Buy | Option Exercise | 13,453 | $585K | 10/8/2021 | View on chart |
| ENTA | ▼ Sell | Open Market | 13,453 | $943K | 10/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
HC Wainwright Maintains $20 Target for Enanta
HC Wainwright reiterated its stance on Enanta Pharmaceuticals, keeping a price target of $20. This view aligns with the broader analyst consensus, where the average target across six analysts is $21.83. The stock is currently trading near its 52-week low, with recent technical signals indicating support at $13.25.
HC Wainwright Maintains $20 Target for Enanta. HC Wainwright reiterated its stance on Enanta Pharmaceuticals, keeping a price target of $20. This view aligns with the broader analyst consensus, where the average target across six analysts is $21.83. The stock is currently trading near its 52-week low, with recent technical signals indicating support at $13.25.